Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could bile acids explain why kids with colitis get more c. diff infections?

NCT ID NCT06228352

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This study looks at bile acid profiles in children with ulcerative colitis (UC) who also have a C. difficile infection. Researchers want to see if changes in bile acids and gut bacteria make these children more vulnerable. They will compare three groups: children with UC flare-ups with or without C. diff, those in remission, and healthy kids. No treatments are given—just stool samples are collected.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal why children with ulcerative colitis are more prone to C. difficile infections, pointing toward future preventive strategies.
What could go wrong
This is an observational study with only 80 participants, so findings may not apply broadly. It does not test any treatment, so direct patient benefits are not expected.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Pediatric patients consulting or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital, with ulcerative colitis (UC) in flare-up with and without Clostridioides difficile infection (CDI), patients UC in remission and healthy controls.

Ages

Up to 17 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

For everyone : Inclusion Criteria: * Pediatric patients (\<18 years) consultant or hospitalized in the Gastroenterology department of Necker-Enfants Malades Hospital. * Information and consent of parents and the patient Exclusion Criteria: * Patient who received antibiotic or antifungal treatment in the 4 weeks prior to inclusion. * Patients colonized by C. difficile. * Pregnant or breastfeeding young girl. * Refusal of the protocol by parents or patient. For group 1: Patients with active UC Inclusion criteria: * Patient with UC, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria. * UC in flare defined by a PUCAI score of between 35 and 65. Non-inclusion criteria: * Patient with IBD unclassified or Crohn's disease. * Patient with isolated proctitis (\<5 cm). * Colectomized patients. * Patients with sclerosing cholangitis associated with their UC or liver disease. Group 2: Patients in UC remission Inclusion criteria: * Patient with UC, whatever the extent, except isolated proctitis (\<5 cm), diagnosed for more than 3 months according to the usual clinical, biological and endoscopic criteria. * UC in remission defined by a PUCAI score \<10. Non-inclusion criteria: * Patient with IBD unclassified or Crohn's disease. * Patient with isolated proctitis (\<5 cm). * Colectomized patients. * Patients with sclerosing cholangitis associated with their UC or liver disease. Group 3: Healthy control subjects Inclusion criteria: \- Patients hospitalized for an endoscopic assessment to control for abdominal pain, gastroesophageal reflux or polyposis. Non-inclusion criteria: * Patient with chronic liver disease. * Patient with chronic digestive disease (celiac disease, IBD, chronic chronic).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ulcerative colitis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Hôpital Necker-Enfants Malades

    RECRUITING

    Paris, 75015, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.